Comment on "Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis".
作者信息
Ding Niu, Chen Tao, Chen Yanping
机构信息
Department of Respiratory Medicine, Hunan Children's Hospital, Changsha, Hunan Province, China.
Department of Pulmonary and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan Province, P.R.China.
出版信息
Int J Surg. 2025 Jun 1;111(6):4136-4137. doi: 10.1097/JS9.0000000000002412. Epub 2025 Apr 22.
Abstract
摘要
相似文献
1
Comment on "Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis".关于《评估病理完全缓解作为非小细胞肺癌患者长期生存的替代终点：一项系统评价和荟萃分析》的述评
Int J Surg. 2025 Jun 1;111(6):4136-4137. doi: 10.1097/JS9.0000000000002412. Epub 2025 Apr 22.
2
Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis.评估病理完全缓解作为非小细胞肺癌患者长期生存的替代终点：一项系统评价和荟萃分析。
Int J Surg. 2025 Apr 1;111(4):3145. doi: 10.1097/JS9.0000000000002381.
3
Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis.评估病理完全缓解作为非小细胞肺癌患者长期生存的替代终点：一项系统评价和荟萃分析。
Int J Surg. 2025 Feb 1;111(2):2216-2226. doi: 10.1097/JS9.0000000000002183.
4
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.评估新辅助随机临床试验中早期乳腺癌的病理完全缓解作为替代终点：系统评价和荟萃分析。
BMJ. 2021 Dec 21;375:e066381. doi: 10.1136/bmj-2021-066381.
5
Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis.用病理缓解作为食管癌新辅助研究中总生存期替代指标的有效性：系统评价和荟萃分析。
Ann Surg Oncol. 2023 Nov;30(12):7461-7471. doi: 10.1245/s10434-023-13778-9. Epub 2023 Jul 3.
6
Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.可切除非小细胞肺癌的病理反应：系统文献回顾和荟萃分析。
JNCI Cancer Spectr. 2024 Apr 30;8(3). doi: 10.1093/jncics/pkae021.
7
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.可切除非小细胞肺癌新辅助化疗后的病理反应：建议将主要病理反应用作替代终点。
Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6.
8
Revisiting surrogacy of pathological complete response for long-term survival in triple-negative breast cancer.重新审视三阴性乳腺癌病理完全缓解作为长期生存替代指标的意义
JNCI Cancer Spectr. 2025 Mar 3;9(2). doi: 10.1093/jncics/pkaf022.
9
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.恶性肿瘤临床试验中短期替代终点指标与mPFS和mOS的关系：以中国批准的非小细胞肺癌分子靶向药物为例
Front Pharmacol. 2022 Mar 16;13:862640. doi: 10.3389/fphar.2022.862640. eCollection 2022.
10
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.乳腺癌的病理完全缓解和长期临床获益：CTNeoBC 汇总分析。
Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14.
本文引用的文献
1
Evaluating pathological complete response as an surrogate endpoint for long-term survival in patients with non-small cell lung cancer: a systematic review and meta-analysis.评估病理完全缓解作为非小细胞肺癌患者长期生存的替代终点：一项系统评价和荟萃分析。
Int J Surg. 2025 Feb 1;111(2):2216-2226. doi: 10.1097/JS9.0000000000002183.
Zotero 插件